Dr Reddys launches generic version of Albenza Tablets in US

Published On 2021-04-30 08:15 GMT   |   Update On 2021-04-30 12:51 GMT
Advertisement

Hyderabad and Princeton: Drugmaker, Dr. Reddy's Laboratories Ltd., has recently announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).

Albendazole is an anthelmintic drug indicated for:

• Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 

• Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Dr. Reddy's Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

Read also: Merck inks licensing pact with Cipla, Sun Pharma, 3 others for oral COVID drug Molnupiravir

Albenza is a trademark of Glaxosmithkline.

The Albenza brand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve months ending in November 2020 according to IQVIA Health*.





Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News